Contact information
Research Groups
DPhil Opportunities
1. "Predicting and characterising asthma exacerbations using a contactless respiratory night monitor".
Available now under the Oxford- MRC DTP iCASE 20226 programme. See link
2. "Novel cardiorespiratory physiological techniques for improving phenotyping of respiratory diseases"
Available now under NDM DPhil Themes. See link.
Nayia Petousi
MA MB BChir MRCP DPhil
Associate Professor & Consultant Physician in Respiratory Medicine
Research Biography and Interests
Short Biography
I am a Consultant Respiratory Physician at Oxford University Hospitals and a Senior Clinical Research Fellow in Respiratory Medicine at the Nuffield Department of Medicine.
I hold a degree in Medicine (MB BChir) from the University of Cambridge. After a period of speciality training in Addenbrooke’s and Papworth Hospital as a respiratory registrar, I came to Oxford in 2009 to study for a DPhil in Biomedical Basic Sciences (Physiology), funded by a Wellcome Trust Fellowship, supervised by Professor Sir Peter Ratcliffe and Professor Peter Robbins. Following my DPhil in 2013, I continued my academic and clinical training at Oxford, as a NIHR academic clinical lecturer, which I completed in 2018.
Research Interests and current projects:
My research interests are in integrative cardiorespiratory physiology, type-2 airways inflammation and airways diseases.
The overarching aim of my work is to "Predict & Prevent" respiratory disease (airways diseases such asthma and COPD): bring disease detection upstream, predict who is at risk and intervene to prevent airway remodelling and progressive lung damage.
I lead translational research on physiological phenotyping of airways diseases using novel non-invasive physiological techniques, such as Computed Cardiopulmonography (CCP), aiming to improve early disease detection, more accurately assess disease progression or treatment response and identify novel treatable traits for better targeting of treatments. CCP consists of a novel technology, the Molecular Flow Sensor (developed by Professor Peter Robbins' & Prof Grant Ritchie's groups in DPAG & Chemistry) that accurately measures respired gases with unprecedented precision, coupled with a new computational cardiopulmonary model. We are using CCP to quantify lung inhomogeneity (unevemness) to phenotype and endotype airways diseases in combination with other biomarkers of disease in blood, sputum, breath. We have shown that a novel measure of inhomogeneity (uneveness) in lung ventilation, termed sigma-CL, is very sensitive in picking up early changes in the small-airways of the lungs, where disease typically begins.
Additionally, I am particularly interested in the role of type-2 inflammation as a driver of progressive respiratory morbidity, and whether early disease detection and intervention (with type-2 targeted therapies) can alter this trajectory.
I supervise DPhil students, post-doctoral researchers and clinical research nurses on a variety of clinical research, physiology and basic science projects, and also serve as local Principal Investigator on several clinical trials (RCT)s.
Current research projects:
1. TREETOP study: This project, funded by Asthma+Lung UK, evaluates CCP as a novel sensitive lung test for the early detection of COPD in people at high risk through tobacco smoking, but who currently have no respiratory diagnosis and normal spirometry. (Post-doctoral Research Scientist: Dr Nick Smith)
2. Estimation of NO depth production in the airways: Using a novel rapid exhaled NO sensor (developed by Grant Ritchie and Lorenzo Petralia in Chemistry) we are assessing relationships between depth of NO production (estimated with a new computational approach: FeNO wall paper) in the lung, and clinical phenotypic characteristics and treatment effects in patients with asthma (DPhil student: Haopeng Xu).
3. Type-2 airway inflammation as a driver of progressive respiratory morbidity: A Predict and Prevent Approach in Obstructive Airways Disease (DPhil student: Mia Cokljat).
I am always happy to discuss research projects with prospective DPhil or Masters students.
Key publications
-
A new piece in the puzzle: the eosinophil and the development of COPD
Journal article
Petousi N. et al, (2021), European Respiratory Journal, 58, 2101105 - 2101105
-
Measuring lung function in airways diseases: current and emerging techniques
Journal article
Petousi N. et al, (2019), Thorax, 74, 797 - 805
-
Sub‐stratification of type‐2 high airway disease for therapeutic decision‐making: A ‘bomb’ (blood eosinophils) meets ‘magnet’ ( FeNO ) framework
Journal article
Couillard S. et al, (2022), Respirology, 27, 573 - 577
-
Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge
Journal article
Raman B. et al, (2021), EClinicalMedicine, 31, 100683 - 100683
-
Successful awake proning is associated with improved clinical outcomes in patients with COVID-19: single-centre high-dependency unit experience
Journal article
Hallifax RJ. et al, (2020), BMJ Open Respiratory Research, 7, e000678 - e000678
-
Transcriptomic analysis identifies a unique, intermittent hypoxia mediated inflammatory profile: evidence from a cross-over randomised CPAP withdrawal trial, with and without supplemental oxygen, in OSA
Conference paper
Turnbull C. et al, (2018), EUROPEAN RESPIRATORY JOURNAL, 52
-
Novel measure of lung function for assessing disease activity in asthma
Journal article
Smith NMJ. et al, (2020), BMJ Open Respiratory Research, 7, e000531 - e000531
Recent publications
-
Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment
Journal article
Lavoie G. et al, (2025), Thorax, 80, 113 - 116
-
Effects of biologic therapy on novel indices of lung inhomogeneity in patients with severe type-2 high asthma
Journal article
Alamoudi A. et al, (2025), BMJ Open Respiratory Research, 12, e002721 - e002721
-
Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment.
Journal article
Lavoie G. et al, (2024), Thorax
-
The effect of supplemental oxygen and continuous positive airway pressure withdrawal on endocan levels
Journal article
Turnbull CD. et al, (2024), Sleep and Breathing, 28, 2509 - 2514
-
Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK
Journal article
Taquet M. et al, (2024), The Lancet Psychiatry, 11, 696 - 708
-
Long-term impact of COVID-19 hospitalisation among individuals with pre-existing airway diseases in the UK: a multicentre, longitudinal cohort study - PHOSP-COVID.
Journal article
Elneima O. et al, (2024), ERJ open research, 10, 982 - 2023
-
Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease
Journal article
Liew F. et al, (2024), Nature Immunology, 25, 607 - 621
-
Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics.
Journal article
Bourdin A. et al, (2024), The journal of allergy and clinical immunology. In practice, 12, 809 - 823
-
Type-2 inflammation: a key treatable trait associated with lung function decline in chronic airways disease
Journal article
Petousi N. et al, (2024), Thorax
-
Computed Cardiopulmonography for the Detection of Early Smoking-Related Changes in the Lungs of Young Individuals Who Smoke.
Journal article
Redmond JL. et al, (2024), Chest
-
Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study
Journal article
Raman B. et al, (2023), The Lancet Respiratory Medicine, 11, 1003 - 1019
-
Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study
Journal article
Jackson C. et al, (2023), The Lancet Respiratory Medicine, 11, 673 - 684
-
Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls
Journal article
Zheng B. et al, (2023), The Lancet Regional Health - Europe, 29, 100635 - 100635
-
The Lancet COPD Commission: broader questions remain
Journal article
Petousi N. et al, (2023), The Lancet, 401, 1569 - 1570
-
Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study
Journal article
McAuley HJC. et al, (2023), eClinicalMedicine, 57, 101896 - 101896
-
Persistence of inflammatory and vascular mediators 5 months after hospitalization with COVID-19 infection
Journal article
Melhorn J. et al, (2023), Frontiers in Medicine, 10
-
Toward a Predict and Prevent Approach in Obstructive Airway Diseases.
Journal article
Couillard S. et al, (2023), J Allergy Clin Immunol Pract
-
Editorial: Physiological phenotyping in respiratory diseases: New approaches.
Journal article
King GG. et al, (2023), Frontiers in physiology, 14
-
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
Journal article
Liew F. et al, (2023), eBioMedicine, 87, 104402 - 104402
-
The Effect of Supplemental Oxygen on Hemoglobin Levels in Obstructive Sleep Apnea
Conference paper
Turnbull CD. et al, (2023), AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 207
